Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nasacort, Flonase Competition Heats Up As Sanofi Appeals NAD Review

This article was originally published in The Tan Sheet

Executive Summary

Chattem appeals a National Advertising Division decision from a review of advertising comparing its Nasacort nasal allergy spray to GSK’s Flonase. The Sanofi business maintains NAD relied on a “cookbook” approach to determine whether claims for the product are substantiated.

Advertisement

Related Content

Children's Flonase Is Latest Play For Nasal Allergy Spray Market Share
Clarion Brands Argues NAD Turns Deaf Ear To Tinnitus Claims Review
Bayer, Chattem Sneeze At NAD Decision On Claritin And Nasacort Comparison
Nasacort 24HR Superiority Claims OK Without Head-To-Head Tests – NAD
Adulturated red yeast rice

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS107893

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel